Phase I/II, open-label, Adaptive Study of Oral Bruton tyrosine kinase inhibitor PRN1008 in patients with relapsed/refractory primary or secondary immune thrombocytopenia - Kuter, D J; Boccia, R V; Lee, E-J (Blood, 2019)
et al.